Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success of anti-CD19 chimeric antigen receptor (CAR) T cell therapies against B-lineage malignancie...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Mingxue, Li, Minghao, Gao, Lipeng, Geng, Sicong, Wang, Jing, Wang, Yiting, Yan, Zhiqiang, Yu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576380/
https://www.ncbi.nlm.nih.gov/pubmed/28851445
http://dx.doi.org/10.1186/s13045-017-0519-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576380/
https://www.ncbi.nlm.nih.gov/pubmed/28851445
http://dx.doi.org/10.1186/s13045-017-0519-7

Ejemplares similares